Integer Holdings Corp

Latest Results (05.04.2026):

Integer Holdings Corp's fourth quarter 2025 results: the company reported solid revenue growth and sizable gains in adjusted profitability. For Q4 2025, sales rose to $472.1M (+5% year-over-year) and adjusted EPS improved to $1.76 (+23%); for full year 2025, Integer delivered $1.854B in sales (+8%) and adjusted EPS of $6.40 (+21%).

Quarter (Q4 2025) results

Sales $472.1M (+5% vs. Q4 2024); GAAP operating income $56M (−2%); adjusted operating income $83M (+10%); GAAP income from continuing operations $49M (+47%); adjusted net income $62M (+22%); GAAP diluted EPS $1.38 (+52%); adjusted EPS $1.76 (+23%); adjusted EBITDA $106M (+11%); repurchased 698,356 shares for $50M.

Full year 2025

Sales $1.8536B (+8%); GAAP operating income $221M (+6%); adjusted operating income $321M (+13%); GAAP income from continuing operations $103M (−15%); adjusted net income $226M (+23%); GAAP diluted EPS $2.89 (−15%); adjusted EPS $6.40 (+21%); adjusted EBITDA $402M (+12%); operating cash flow $196M.

Product-line performance

Cardio & Vascular: Q4 $284.2M (+11%), FY $1.107B (+17%) — driven by acquisitions, neurovascular strength and EP ramps. Cardiac Rhythm Management & Neuromodulation: Q4 $167.3M (−2%), FY $668.8M (+1%) — neuromodulation softness from select emerging customers. Other Markets: Q4 $20.5M (−13%), FY $77.8M (−27%) due to the multi-year Portable Medical exit.

Balance sheet & liquidity

Total debt $1.185B (up $195M year-over-year); non‑GAAP net total debt $1.190B; leverage 3.0x trailing adjusted EBITDA. Cash and cash equivalents $17.2M at year end; 2025 capex $91M.

Share repurchase & capital actions

Completed repurchases of ~698k shares for $50M in the quarter and announced intent to commence an accelerated share repurchase (ASR) to repurchase approximately $50M more under the existing $200M authorization, to be funded by cash and borrowings.

2026 outlook

2026 GAAP sales guidance $1.826–1.876B (≈ flat year-over-year); GAAP diluted EPS $3.53–4.01 (up 22–39%); non‑GAAP adjusted EPS $6.29–6.78 (−2% to +6%); adjusted EBITDA $391–414M; cash from operations $200–220M; capex $95–105M; expected leverage 2.5–3.5x. Company reiterated expectation to return to ~200 bps above-market organic sales growth in 2027.

Non‑GAAP and reconciliation notes

Integer emphasizes adjusted measures (adjusted operating income, adjusted net income/EPS, adjusted EBITDA, organic sales) that exclude items such as amortization of intangibles, acquisition/integration costs, restructuring, ERP implementation and other discrete items; reconciliations are included in the release.